Core Viewpoint - Gain Therapeutics has appointed Gene Mack as President and Chief Executive Officer, effective January 6, 2025, to ensure continuity in leadership as the company advances its lead drug candidate, GT-02287, through clinical development [1][2]. Leadership Changes - Gene Mack has been promoted from Chief Financial Officer and interim Chief Executive Officer to President and Chief Executive Officer, and he will also join the Board of Directors [1][2]. - Gianluca Fuggetta has been appointed as Senior Vice President, Finance and Principal Financial Officer [1]. Gene Mack's Background - Gene Mack brings over 25 years of experience in the life sciences sector, including roles in clinical research, financing, corporate strategy, and business development [3]. - Prior to joining Gain Therapeutics, he served as CFO at Imcyse SA and OncoC4, and has experience as a senior publishing analyst at various investment banks [3]. Drug Candidate Overview - GT-02287 is in clinical development for treating Parkinson's disease, targeting both GBA1 mutation and idiopathic forms [4][7]. - The drug is an orally administered, brain-penetrant small molecule that acts as an allosteric protein modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [4]. Clinical Development and Support - GT-02287 has shown promising preclinical results, including restoration of GCase function and reduction of neuroinflammation and neuronal death [4][5]. - The program has received funding support from The Michael J. Fox Foundation and other organizations, indicating strong backing for its development [6]. Future Plans - The ongoing Phase 1b trial for GT-02287 in Parkinson's disease patients is expected to continue into the first half of 2025, with preparations for potential Phase 2 activities in the second half of 2025 [3].
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director